The recent 21% drop in Hims & Hers (HIMS) stock is viewed as a buying opportunity based on a market overreaction to GLP-1 drug pricing news. The investment thesis is that HIMS is a diversified telehealth platform, not just a weight-loss company, with strong core businesses in areas like erectile dysfunction and anxiety. Hims' primary value is its bundled, affordable access to doctors, which remains compelling regardless of drug prices. The company is also insulated by its successful, lower-cost weight loss alternatives, including an oral kit starting at $69/month. In contrast, investors should be aware that major GLP-1 producers like Novo Nordisk (NVO) and Eli Lilly (LLY) carry significant political headline risk and volatility.

Hims & Hers Health, Inc. (HIMS)

• The stock experienced a significant drop, down 14% on the day of the podcast and 21% from its recent peak.
• The primary reason for the decline was news that former President Trump was touting his ability to secure much lower prices for GLP-1 drugs like Ozempic.
• A secondary, and less significant, reason mentioned was a $20-30 million share sale by the CEO. The speaker dismisses this as a non-issue, citing that CEOs have many reasons to sell (taxes, charity) and it didn't meaningfully impact his ownership.
• The speaker argues the market is incorrectly viewing HIMS as a pure GLP-1 company, causing it to overreact to this news.
• The market is ignoring Hims' other business lines:
  • The recently launched menopause vertical.
  • The core Erectile Dysfunction (ED) drug business, which is still its #1 seller.
  • The large anxiety/SSRI medication business.
  • The "Hers" brand, which is projected to become a billion-dollar business by 2026.
• The speaker emphasizes that Hims' core value proposition is not just selling cheap drugs, but providing affordable and convenient access to doctors.
  • Hims bundles the cost of doctor visits, prescriptions, and follow-ups into a single, easy-to-understand price.
  • This solves a major pain point for consumers, as individual doctor visits for these prescriptions can cost $250-$500.
• Hims has a diversified weight loss offering beyond expensive GLP-1s:
  • It sells its own vertically integrated, generic liraglutide (a GLP-1) for $299/month, which is already a competitive price.
  • It offers an oral weight loss medication kit, based on drugs like metformin, starting at just $69/month. This non-GLP-1 offering had a revenue run rate of over $100 million several quarters ago and is likely much higher now.

Takeaways

• The speaker views the 21% drop in the stock price as a "buying opportunity" based on a market overreaction.
• The investment thesis is that HIMS is a diversified telehealth platform, not just a GLP-1 company. Its revenue from weight loss is only 20% of the total, yet it drives most of the stock's volatility.
• Even if branded GLP-1 prices fall to $150/month, Hims' business model remains strong because it solves the separate and costly problem of doctor access and prescription management.
• Investors should consider Hims' competitive advantages in its lower-cost weight loss alternatives (like the $69/month oral kit), which appeal to customers who cannot afford or do not want to take GLP-1 injections.

Novo Nordisk (NVO) & Eli Lilly (LLY)

• These major pharmaceutical companies, known for their blockbuster GLP-1 drugs like Ozempic, also saw their stocks fall on Trump's comments about lowering drug prices.
• The discussion frames their GLP-1 franchises as a "cash cow" that is vulnerable to political pressure and potential government-mandated price reductions.
• The speaker expressed skepticism that Trump could successfully force prices down to European levels (e.g., $150/month) due to "entrenched interests" in the U.S. healthcare system.

Takeaways

• Investments in major GLP-1 manufacturers like Novo Nordisk and Eli Lilly carry significant political and headline risk.
• Their stock prices are sensitive to any news or rhetoric about drug price controls, which could impact the profitability of their most successful products.
• While the speaker doubts drastic price cuts will be implemented, investors should be aware that the topic will likely remain a source of volatility for these stocks.